Cutaneous anthrax: Seven cases;Maladie du charbon cutanée : sept cas

Annales de Dermatologie et de Venereologie

Volumn 136, Issue 1, 2009, Pages 9-14

  Chraibi, H ^a   Haouach, K ^a   Azouzi, A Idrissi ^b   Gaamouche, K ^c   Kaidi, A ^c   Khalidi, T El ^c   Alifadl, A ^a   Bjani, L ^a   Mountasser, A ^a  

^a Mohammed V Hospital   (Morocco)

^b Direction d'épidémiologie ^*  (Morocco)

^c hôpital civil de Tétouan   (Morocco)

Author keywords

Anthrax; Bacillus anthracis; Morocco

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CORTICOSTEROID; DOXYCYCLINE; OXACILLIN; PENICILLIN G; POVIDONE IODINE; PREDNISONE;

ADULT; ANTHRAX; ARM; ARTICLE; BACILLUS ANTHRACIS; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DISEASE CARRIER; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL SYMPTOM; GOAT; HUMAN; ISOLATION PROCEDURE; MALE; SEPTICEMIA; SKIN DEFECT; VACCINATION;

ADOLESCENT; ADULT; ANIMALS; ANTHRAX; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN DISEASES, BACTERIAL; UPPER EXTREMITY; YOUNG ADULT; ZOONOSES;

EID: 61349139408     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2008.10.021     Document Type: Article

References (13)

1. Carsuzaa F., Debord T., Boye T., Cavallo J.D., Pierre C., Vidal D., et al. Manifestations cutanées du bioterrorisme infectieux. Ann Dermatol Venereol 129 (2002) 81-84
2. Turnbull PC. Guidelines for the surveillance and control of anthrax in humans and animals. Geneva, Switzerland: World Health Organization, Department of Communicable Diseases Surveillance and Response, 1998;WHO/EMC/ZDI./98.6.
3. Bossi P., and Bricaire F. La maladie du charbon à l'heure du bioterrorisme. Presse Med 32 (2003) 167-173
4. Pile J.C., Malone J.D., Eitzen E.M., and Friedlander A.M. Anthrax as a potential biological warfare agent. Arch Intern Med 158 (1998) 429-434
5. Swartz M.N. Recognition and management of anthrax-an update. N Engl J Med 345 (2001) 1621-1626
6. Bulletin épidémiologique. Archives du service des maladies épidémiques, c2003-2007 ; ministère de la Santé, Rabat, Maroc. www.sante.gov.ma/Departments/DELM/bulletins.htm. (consulté en septembre 2008).
7. Bartlett J.G., Inglesby Jr. T.V., and Borio L. Management of anthrax. Clin Infect Dis 35 (2002) 851-858
8. Wenner K.A., and Kenner J.R. Anthrax. Dermatol Clin 22 (2004) 247-256
9. Carucci J.A., McGovern T.W., Norton S.A., Daniel C.R., Elewski B.E., Fallon-Friedlander S., et al. Cutaneous anthrax management algorithm. J Am Acad Dermatol 47 (2002) 766-769
10. Athamna A., Athamna M., Abu-Rashed N., Medlej B., Bast D.J., and Rubinstein E. Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 54 (2004) 424-428
11. Stern E.J., Uhde K.B., Shadomy S.V., and Messonnier N. Conference Report on Public Health and Clinical Guidelines for Anthrax. Emerg Infect Dis (2008) 14.pii:07-0969
12. Spencer R.C. Bacillus anthracis. J Clin Pathol 56 (2003) 182-187
13. Center for Disease Control and Prevention. Use of anthrax vaccine in the United States; recommendations of the advisory committee on immunization practices (ACIP). MMWR 2000; 4:RR-15.